AM1172 (a hydrolysis-resistant endocannabinoid analog that inhibits anandamide cellular uptake) reduces the viability of the various melanoma cells, but it exerts significant cytotoxic effects on healthy cells: an in vitro study based on isobolographic analysis.

Autor: Marzęda P; Department of Occupational Medicine, Medical University of Lublin, 20-090, Lublin, Poland., Wróblewska-Łuczka P; Department of Occupational Medicine, Medical University of Lublin, 20-090, Lublin, Poland., Florek-Łuszczki M; Department of Medical Anthropology, Institute of Rural Health, 20-950, Lublin, Poland., Góralczyk A; Department of Occupational Medicine, Medical University of Lublin, 20-090, Lublin, Poland., Łuszczki JJ; Department of Occupational Medicine, Medical University of Lublin, 20-090, Lublin, Poland. jarogniew.luszczki@umlub.pl.
Jazyk: angličtina
Zdroj: Pharmacological reports : PR [Pharmacol Rep] 2024 Feb; Vol. 76 (1), pp. 154-170. Date of Electronic Publication: 2023 Nov 29.
DOI: 10.1007/s43440-023-00557-2
Abstrakt: Background: Despite great advances in our understanding of the impact of cannabinoids on human organism, many of their properties still remain undetermined, including their potential antineoplastic effects. This study was designed to assess the anti-proliferative and cytotoxic effects of AM1172 (a hydrolysis-resistant endocannabinoid analog that inhibits anandamide cellular uptake) administered alone and in combinations with docetaxel (DOCX), paclitaxel (PACX), mitoxantrone (MTX) and cisplatin (CDDP) on various human malignant melanoma A375, FM55P, SK-MEL 28 and FM55M2 cell lines.
Materials: In the MTT, LDH, and BrdU assays, the potency and safety of AM1172 when administered alone and in combinations with DOCX, PACX, MTX, and CDDP were determined.
Results: The isobolographic analysis revealed that combinations of AM1172 with PACX, DOCX, MTX, and CDDP exerted additive interactions, except for a combination of AM1172 with PACX in primary melanoma A375 cell line, for which synergy was observed (*p<0.05). Nevertheless, AM1172 when administered alone produced cytotoxic effects on healthy human melanocytes (HEMa-LP) and human keratinocytes (HaCaT), which unfortunately limits its potential therapeutic utility.
Conclusions: AM1172 cannot be used separately as a chemotherapeutic drug, but it can be combined with PACX, DOCX, MTX, and CDDP, offering additive interactions in terms of the anti-proliferative effects in various malignant melanoma cell lines.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: